High-throughput structural biology in drug discovery: Protein kinases

Current Pharmaceutical Design

Volumn 10, Issue 10, 2004, Pages 1069-1082

  Stout, T J ^a   Foster, P G ^a   Matthews, D J ^a  

^a EXELIXIS INC   (United States)

Author keywords

Crystallography; Lead optimization; Protein structure

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 7 HYDROXYSTAUROSPORINE; ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; OXINDOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN SERINE KINASE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SB 281832; STAUROSPORINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL CYCLE; DIABETES MELLITUS; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; INFLAMMATION; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MYELOID LEUKEMIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SUBSTRATE SPECIFICITY;

EID: 1842431419     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452695     Document Type: Review

References (147)

1. Stevens RC. The cost and value of three-dimensional protein structure. Drug Discovery World 2003; 4(3): 35-48.
2. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-398.
3. Hubbard S. Protein tyrosine kinases: Autoregulation and small-molecule inhibition. Curr Opin Struct Biol 2002; 12: 735-741.
4. Scapin G. Structural biology in drug design: Selective protein kinase inhibitors. Drug Discovery Today 2002; 7(11): 601-611.
5. Williams DH, Mitchell T. Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr Opin Pharmacol 2002; 2: 1-7.
6. Nienaber VL, et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 2000; 18(10): 1105-1108.
7. Blundell TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 2002; 1(1): 45-54.
8. Pellechia M, Sem DS, Wüthrich K. NMR in Drug Discovery. Nat Rev Drug Discov 2002; 1: 211-219.
9. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411(6835): 355-365.
10. Druker BJ, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2(5): 561-6.
11. Druker B. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother 2003; 4(6): 963-971.
12. Druker BJ, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038-1042.
13. Cohen MH, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2003; 8(5): 935-942.
14. Dagher R, et al. Approval summary: Imatinib niesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002: 8(10): 3034-3038.
15. Lee JC, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47: 185-201.
16. Vlahos CJ, McDowell SA, Clerk A. Kinases as therapeutic targets for heart failure. Nat Rev Drug Discov 2003; 2: 99-113.
17. Jiang G, Zhang BB. P13-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes. Front Biosci 2002; 7: 903-7.
18. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359((Pt 1): 1-16.
19. Mucke HA. CEP-1347 (Cephalon). IDrugs 2003; 6(4): 377-83.
20. Manning G, et al. The protein kinase complement of the human genome. Science 2002; 298(5600): 1912-34.
21. Brunelleschi S, et al. Receptor tyrosine kinases as target for anti-cancer therapy. Curr Pharm Des 2002; 8: 1959-1972.
22. Fabbro D, Parkinson D, Matter A. Protein tyrosine kinase inhibitors: New treatment modalities? Curr Opin Pharmacol 2002; 2: 374-381.
23. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer, 2002. 38(Suppl 5): S11-S18.
24. Grünwald V, Hidalgo M. Developing Inhibitors of tile Epidermal Growth Factor Receptor for Cancer Treatment. J Natl Cancer Inst 2003; 95(12): 851-867.
25. Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003; 7(2): 215-234.
26. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001: 7: 2958-2970.
27. Hidalgo M, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
28. Laird AD, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Research 2000; 60(15): 4152-60.
29. Cohen MH, et al. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8(4): 303-306.
30. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: Toward novel use of kinase inhibitors (outlook). Cancer Biol Ther 2003; 2(2): 137-140.
31. Dancey JF, Freidlin B. Targeting epidermal growth factor receptor--are we missing the mark? Lancet 2003: 362(9377): 62-64.
32. Orchard S. Kinases as targets: Prospects for chronic therapy. Curr Opin Drug Discov Devel 2002; 5(5): 713-7.
33. Braddock M. Inflammation in Drug Discovery and Development--SRI's Seventh International Meeting. 20-21 February 2003, San Diego, USA. IDrugs 2003; 6(4): 318-22.
34. Vermeulen KD, Van Bockstaele R, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36(3): 131-149.
35. Senderowicz AM. Cyclin-depenclent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif 2002; 20: 169-196.
36. Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 2003; 3(4): 362-70.
37. Li Q, Zhu G.-D. Targeting Serine/Threonine Protein Kinase B/Akt and Cell Cycle Checkpoint Kinases for Treating Cancer. Current Topics in Medicinal Chemistry 2002; 2: 939-971.
38. Huang X, et al. Crystal structure of an inactive akt2 kinase domain. Structure 2003: 11(1): 21-30.
39. Yang J, et al. Crystal structure of ail activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol 2002; 9(12): 940-4.
40. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 2003; 24(3): 139-145.
41. Tenzer A, Pruschy M. Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr Med Chem Anti-Canc Agents 2003; 3(1): 35-46.
42. Chen P, et al. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: Implications for Chk1 regulation. Cell 2000; 100(6): 681-92.
43. Zhao B, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002; 277(48): 46609-46615.
44. Laird AD, et al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002; 16(7): 681-690.
45. Shi Y. Mammalian RNAi for the masses. Trends Genet 2003: 19(1): 9-12.
46. Zaman GJR, et al. Fluorescence Assays for High-Throughput Screening of Protein Kinases. Combinatorial Chemistry and High Throughput Screening 2003; 6: 313-320.
47. Rossman M. Molecular Replacment Method. Int Sci Rev Ser 1972; 13: 173-178.
48. Knighton DR, et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991; 253(5018): 407-414.
49. Johnson LN, Noble ME, Owen DJ. Active and inactive protein kinases: Structural basis for regulation. Cell 1996; 85(149-158).
50. Hubbard SR. Src autoinhibition: Let us count the ways. Nat Struct Biol 1999; 6(8): 711-714.
51. Adams JA. Activation loop phosphorylation and catalysis in protein kinases: Is there functional evidence for the autoinhibitor model? Biochemistry 2003; 42(3): 601-7.
52. Toker AN, Newton AC. Cellular Signaling: Pivoting around PDK1. Cell 2000; 103: 185-188.
53. Till JH, et al. Crystallographic and Solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: Insights into kinase mechanism. J Biol Chem 2001; 276(13): 10049-55.
54. Ablooglu AJ, et al. Multiple activation loop conformations and their regulatory properties in the insulin receptor's kinase domain. J Biol Chem 2001; 276(50): 46933-40.
55. Orr JW, Newton AC. Requirement for negative charge on "aCtivatioO loop" of protein kinase C. J Biol Chem 1994; 269(44): 27715-8.
56. Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996; 384(6608): 484-9.
57. Jeffrey PD, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995; 376(6538): 313-320.
58. De Bondt HL, et al. Crystal structure of cyclin-dependent kinase 2. Nature 1993; 363(6430): 595-602.
59. Collins BJ, et al. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J 2003; 22(16): 4202-11.
60. Biondi RM, et al. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 2001; 20(16): 4380-90.
61. Frodin M, et al. A pliosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation. EMBO J 2002; 21(20): 5396-407.
62. Biondi RM, et al. High resolution crystal structure of the human PDK1 catalytic domain defines tile regulatory phosphopeptide docking site. EMBO J 2002; 21(16): 4219-28.
63. Biondi RM, et al. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J 2000; 19(5): 979-88.
64. Komander D. et al. Structural basis for UCN-01 specificity and PDK1 inhibition. Biochemical Journal, 2003; E-publication 1 Aug 2003.
65. Balendran A, et al. Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 1999; 274(52): 37400-6.
66. Balendran, A, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol 1999; 9(8): 393-404.
67. Wybenga-Groot LE, et al. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001; 106(6): 745-757.
68. Shewchuk LM, et al. Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail. Structure Fold Des 2000; 8(11): 1105-13.
69. Underwood KW, et al. Catalytically active MAP KAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme. Structure 2003; 11(6): 627-636.
70. Meng W, et al. Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J Biol Chem 2002; 277(40); 37401-37405.
71. Xu W, et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999; 3(5): 629-38.
72. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997; 385(6617): 595-602.
73. Moarefi I, et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 1997; 385(6617): 650-653.
74. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997; 385(6617): 602-609.
75. Laird AD, Cherrington JM. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Expert Opin. Investig. Drugs 2003; 12(1): 51-64.
76. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309-315.
77. Lawrie AM, et al. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol 1997. 4(10): 796-801.
78. Prade L, et al. Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997; 5(12): 1627-1637.
79. Walker EH, et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999; 402(6759): 313-320.
80. Zhu, X, et al. Structural Analysis of the Lymphocyte-Specific Kinase Lck in Complex with Non-Selective and Src Family Selective Kinase. Structure Fold Des 1999; 7(6): 651-661.
81. Lamers MB, et al. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J Mol Biol 1999; 285(2): 713-725.
82. Nagar B, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research 2002; 62(15): 4236-43.
83. Mohammadi M, et al. Crystal Structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17(20): 5896-5904.
84. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor. J Biol Chem 2002; 277(48): 46265-72.
85. Shewchuk L, et al. Binding nriode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 2000; 43(1): 133-8.
86. Davis ST, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001; 291(5501): 134-7.
87. Mashhoon N, et al. Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem 2000; 275(26): 20052-60.
88. Davies TG, et al. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (Camb) 2001; 9(5): 389-97.
89. Bramson H, et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J Med Chem 2001; 44(25): 4339-58.
90. Mohammadi M, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997; 276(5314): 955-60.
91. Knighton DR, et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991; 253(5018): 414-20.
92. Parang K, et al. Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 2001; 8(1): 37-41.
93. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997; 16(18): 5572-81.
94. Pargellis C, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Structural Biology 2002; 9(4): 268- 272.
95. Schindler T, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000: 289(5486): 1938-42.
96. Thornton J. Structural Genomics takes off. Trends Biochem Sci 2001; 26: 88-90.
97. Stevens RC, Yokoyama S, Wilson IA. Global efforts in structural genomics. Science 2001; 294: 89-92.
98. Heinemann U, Büssow K, Mueller U, Umbach P. Facilities and Methods for High-Throughput Crystal Structural Analysis of Human Proteins. Acc Chem Res 2003; 36(3): 157-163.
99. Stevens RC, High-throughput protein crystallization. Curr Opin Struct Biol 2000; 10(5): 558-63.
100. Henikoff S, Pietrokovski S, Henikoff JG. Superior performance in protein homology detection with the Blocks Database servers. Nucleic Acids Res 1998; 26(1): 309-12.
101. Madera M, Gough JA. Comparison of profile hidden Markov model procedures for remote homology detection. Nucleic Acids Res 2002; 30(19): 4321-8.
102. Hubbard SJ. The structural aspects of limited proteolysis of native proteins. Biochim Biophys Acta 1998; 1382(2): 191-206.
103. Wigley WC, et al. Protein solubility and folding monitored in vivo by structural complementation of a genetic marker protein. Nat Biotechnol 2001; 19(2): 131-136.
104. Waldo GS, et al. Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol 1999; 17(7): 691-5.
105. Maxwell KL, et al. A simple in vivo assay for increased protein solubility. Protein Sci 1999; 8(9): 1908-1911.
106. Kapust RB, Waugh DS. Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci 1999; 8(8): 1668-1674.
107. Lesley SA, et al. Gene expression response to misfolded protein as a screen for soluble recombinant protein. Protein Eng 2002; 15(2): 153-60.
108. Thomas JG, Ayling A, Baneyx F. Molecular chaperones, folding catalysts, and the recovery of active recombinant proteins from E. coli. To fold or to retold. Appl Biochem Biotechnol 1997; 66(3): 197-238.
109. Dale GE, Oefner C, D'Arcy A. The protein as a variable in protein crystallization. J Struct Biol 2003; 142(1): 88-97.
110. Judge RA, Forsythe EL, Pusey ML. The effect of protein impurities on lysozyme crystal growth. Biotechnol Bioeng 1998; 59(6): 776-85.
111. Phan J, et al. Structural basis for the substrate specificity of tobacco etch virus protease. J Biol Chem 2002; 277(52): 50564-72.
112. Kapust RB, et al. The P1 specificity of tobacco etch virus protease. Biochemical and Biophysical Research Communications 2002: 294(5): 949-955.
113. Terpe K. Overview of tag protein fusions: From molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2003; 60(5): 523-33.
114. Lanio T, Jeltsch A, Pingoud A. Automated purification of His6-tagged proteins allows exhaustive screening of libraries generated by random mutagenesis. Biotechniques 2000; 29(2): 338-42.
115. D'Arcy A, et al. The advantages of using a modified microbatch method for rapid screening of protein crystallization conditions. Acta Crystallogr D Biol Crystallogr 2003; 59(Pt 2): 396-399.
116. Chayen N. Comparative studies of protein crystallization by vapour-diffusion and microbatch techniques. Acta Crystallogr D Biol Crystallogr, 1998; 54(Pt 1): 8-15.
117. Rupp B. High-throughput crystallography at an affordable cost: The TB Structural Genomics Consortium Crystallization Facility. Acc Chem Res 2003; 36(3): 173-81.
118. Cumbaa CA, et al. Automatic classification of sub-microlitre protein-crystallization trials in 1536-well plates. Acta Crystallogr D Biol Crystallogr 2003; 59(Pt 9): 1619-1628.
119. Krupka HI, et al. The high-speed Hydra-Plus-One system for automated high-throughput protein crystallography. Acta Crystal logr D Biol Crystallogr 2002; 58(Pt 10 Pt 1): 1523-6.
120. Bergfors T. Seeds to crystals. J Struct Biol 2003; 142(1): 66-76.
121. Rodgers DW. Cryocrystallography. Structure 1994; 2(12): 1135-40.
122. Helliwell JR. Synchrotron radiation facilities. Nat Struct Biol 1998; 5 Suppl: 614-7.
123. Hendrickson WA. Synchrotron crystallography. Trends Biochem Sci 2000; 25(12): 637-43.
124. Perrakis A, et al. Protein microcrystals and the design of a microdiffractometer: Current experience and plans at EMBL and ESRF/ID13. Acta Crystallogr D Biol Crystallogr 1999; 55 (Pt 10): 1765-70.
125. McPhillips TM, et al. Blu-Ice and the Distributed Control System: Software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat 2002; 9(Pt 6): 401-6.
126. Cohen AE, et al. An automated system to mount cryo-cooled protein crystals on a synchrotron beamline, using compact sample cassettes and a small-scale robot. J Appl Cryst 2002; 35(6): 720-26.
127. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode., in Methods in Enzymology 1997; p. 307-326.
128. Leslie AG. Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 1999; 55 (Pt 10): 1696-702.
129. Pflugrath JW. The finer things in X-ray diffraction data collection. Acta Crystallogr D Biol Crystallogr 1999; 55 (Pt 10): 1718-25.
130. Dauter Z. Data-collection strategies. Acta Crystallogr D Biol Crystallogr 1999; 55 (Pt 10): 1703-17.
131. Rossman M. and Blow D. The Detection of Sub-Units within the Crystallographic Asymmetric Unit. Acta Cryst 1962; 15: 24-31.
132. Hendrickson WA, et al. Crystallographic structure analysis of lamprey hemoglobin from anomalous dispersion of synchrotron radiation. Proteins 1988; 4(2): 77-88.
133. Hendrickson WA, Horton JR, LeMaster DM. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): A vehicle for direct determination of three-dimensional structure. EMBO J 1990; 9(5): 1665-72.
134. La Fortelle E, Bricogne G. in Methods in Enzymology 1997; p. 472-494.
135. Terwilliger TC, Berendzen J. Automated MAD and MIR structure solution. Acta Crystallogr D Biol Crystallogr 1999; 55 ( Pt 4): 849-61.
136. Van Asselt EJ, et al. Accelerated X-ray structure elucidation of a 36 kDa muramidase/transglycosylase using wARP. Acta Crystallogr D Biol Crystallogr 1998; 54 (Pt 1): 58-73.
137. Terwilliger TC. Automated structure solution, density modification and model building. Acta Crystallogr D Biol Crystallogr 2002; 58(Pt 11): 1937-40.
138. Kraulis PJ. MOLSCRIPT: A Program to Produce Both Detailed and Schematic Plots of Protein Structures. Journal of Applied Crystallography 1991; 24: 946-950.
139. Merritt EA, Bacon DJ. Raster3D: Photorealistic Molecular Graphics. Methods in Enzymology 1997; 277: 505-524.
140. Carson WM. Methods in Enzymology 1997; 277: 493-505.
141. Evans SV. SETOR: Hardware-lighted three dimensional solid model representations of macromolecules. Journal of Molecular Graphics 1993; 11: 134-8.
142. Guex N, Peitsch MC, SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997; 18: 2714-2723.
143. Accelrys, DiscoveryStudio ViewerPro. 2003, Accelrys, Inc.: San Diego, CA USA.
144. DeLano WL. The PyMOL Molecular Graphics System 2002; DeLano Scientific: San Carlos, CA, USA.
145. Hoffren AM, Murray CM, Hoffmann RD. Structure-based focusing using pharmacophores derived from the active site of 17beta-hydroxysteroid dehydrogenase. Curr Pharm Design 2001; 7(7): 547-66.
146. Rockway TW, Nienaber V, Giranda VL. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Design 2002; 8(28): 2541-58.
147. Wouters J, Ooms F. Small molecule crystallography in drug design. Curr Pharm Design 2001; 7(7): 529-45.